While research has predominantly centered on CD4+CD25+FOXP3+ T cells, it is plausible to speculate that CD4+CD25+Foxp3- T cells could potentially influence tumor progression and patient outcomes through analogous mechanisms, thereby warranting further investigation into their role in the complex tumor immune microenvironment. This evidence concerns the gene FOXP3 and neoplasm.